| Literature DB >> 26973020 |
Izabela Nowak1, Andrzej Malinowski2, Ewa Barcz3, Jacek R Wilczyński4, Marta Wagner5, Edyta Majorczyk5,6, Hanna Motak-Pochrzęst6,7, Małgorzata Banasik8, Piotr Kuśnierczyk9.
Abstract
The KIR2DL4 receptor and its ligand HLA-G are considered important for fetal-maternal immune tolerance and successful pregnancy. The absence of a particular variant of KIR2DL4 might be a bad prognostic factor for pregnancy outcome. However, it could be compensated by the presence of the respective LILRB1 allele. Therefore, we investigated the KIR2DL4, LILRB1 and HLA-G polymorphisms in 277 couples with spontaneous abortion and 219 control couples by HRM, PCR-SSP and RFLP methods. We found a protective effect of women's heterozygosity in -716 HLA-G (p = 0.0206) and LILRB1 (p = 0.0131) against spontaneous abortion. Surprisingly, we observed more 9A/10A genotypes of KIR2DL4 gene carriers in the group of male partners from the miscarriage group in comparison to the men from the control group (p = 0.0288). Furthermore, there was no association of women's KIR2DL4 polymorphism with susceptibility to spontaneous abortion. Multivariate analysis indicated that women's -716 HLA-G and LILRB1 and men's KIR2DL4 9A/10A are important in terms of the protection or susceptibility to miscarriage, respectively (p = 0.00968). In conclusion, a woman's heterozygosity in HLA-G and LILRB1 might be an advantage for a success of reproduction, but the partner's heterozygosity in 9A/10A KIR2DL4 alleles might not.Entities:
Keywords: HLA-G; KIR2DL4; LILRB1; Linkage disequilibrium; Spontaneous abortion
Mesh:
Substances:
Year: 2016 PMID: 26973020 PMCID: PMC5085992 DOI: 10.1007/s00005-016-0389-7
Source DB: PubMed Journal: Arch Immunol Ther Exp (Warsz) ISSN: 0004-069X Impact factor: 4.291
Genotype frequencies in women group according to cases and controls
| Polymorphism | Cases A | Cases B | Controlsa | ORb | CI 95 % | Cases vs. controls | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||||||
| HLA-G 14 bp ins/del | del/del | 27 | 34.2 | 73 | 36.9 | 74 | 33.8 | 1 |
| ||
| del/ins | 30 | 38 | 91 | 45.9 | 110 | 50.2 | 0.82 | 0.55 | 1.21 | ||
| ins/ins | 22 | 27.8 | 34 | 17.2 | 35 | 16 | 1.18 | 0.70 | 1.98 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.237 | 0.044 | –0.04 | ||||||||
| HLA-G −725 | CC | 52 | 65.8 | 134 | 67.7 | 152 | 69.4 | 1 |
| ||
| CG | 19 | 24.0 | 50 | 25.3 | 57 | 26 | 0.99 | 0.66 | 1.49 | ||
| CT | 4 | 5.1 | 7 | 3.5 | 5 | 2.3 | 1.71 | 0.61 | 4.83 | ||
| GG | 4 | 5.1 | 6 | 3 | 5 | 2.3 | 1.56 | 0.54 | 4.48 | ||
| GT | 0 | 0 | 1 | 0.5 | 0 | 0 | 2.45 | – | – | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.049 | 0.014 | 0.019 | ||||||||
| HLA-G −716 | TT | 23 | 29.1 | 51 | 25.8 | 58 | 26.5 | 1 |
| ||
| GT | 32 | 40.5 | 102 | 51.5 | 122 | 55.7 | 0.86 | 0.57 | 1.31 | ||
| GG | 24 | 30.4 | 45 | 22.7 | 39 | 17.8 | 1.38 | 0.82 | 2.32 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.189 | –0.031 | –0.122 | ||||||||
| KIR2DL4 9620 | 9A/9A | 22 | 27.8 | 52 | 26.3 | 66 | 30.1 | 1 |
| ||
| 9A/10A | 38 | 48.1 | 100 | 50.5 | 103 | 47 | 1.19 | 0.79 | 1.81 | ||
| 10A/10A | 19 | 24.1 | 46 | 23.2 | 50 | 22.8 | 1.16 | 0.71 | 1.90 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.036 | –0.011 | 0.054 | ||||||||
| KIR2DL4 9571 | TT | 23 | 29.1 | 55 | 27.8 | 71 | 32.4 | 1 |
| ||
| CT | 38 | 48.1 | 100 | 50.5 | 103 | 47 | 1.22 | 0.81 | 1.84 | ||
| CC | 18 | 22.8 | 43 | 21.7 | 45 | 20.5 | 1.23 | 0.75 | 2.03 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.034 | –0.014 | 0.046 | ||||||||
| KIR2DL4 9769 | CC | 53 | 67.1 | 135 | 68.2 | 147 | 67.1 | 1 |
| ||
| CA | 23 | 29.1 | 63 | 31.8 | 66 | 30.1 | 1.02 | 0.69 | 1.50 | ||
| AA | 3 | 3.8 | 0 | 0 | 6 | 2.7 | 0.42 | 0.11 | 1.57 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.0286 | –0.189 | –0.029 | ||||||||
| KIR2DL4 9797 | GG | 23 | 29.1 | 55 | 27.8 | 70 | 32 | 1 |
| ||
| GA | 38 | 48.1 | 100 | 50.5 | 103 | 47 | 1.20 | 0.80 | 1.81 | ||
| AA | 18 | 22.8 | 43 | 21.7 | 46 | 21 | 1.19 | 0.72 | 1.96 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.034 | –0.014 | 0.048 | ||||||||
| LILRB1 5651 | GG | 69 | 87.3 | 172 | 86.9 | 182 | 83.1 | 1 |
| ||
| GA | 10 | 12.7 | 22 | 11.1 | 35 | 16 | 0.69 | 0.41 | 1.16 | ||
| AA | 0 | 0 | 4 | 2 | 2 | 0.9 | 1.36 | 0.29 | 6.46 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| –0.067 | 0.207 | 0.015 | ||||||||
Cases A patients with two miscarriages, Cases B patients with three or more miscarriages, N number of cases, P probability, OR odds ratio, 95 % CI confidence interval, H–W Hardy–Weinberg equilibrium, f < 0 corresponds to deficiency of homozygotes, f > 0 corresponds to excess of homozygotes, f = 0 in case of H–W
aFrequencies of KIR2DL4 polymorphisms in controls were described previously by Nowak et al. (2015)
bOR computed for [cases A plus cases B] vs. controls
Genotype frequencies in men group according to cases and controls
| Polymorphism | Cases A | Cases B | Controlsa | ORb | CI 95 % | Cases vs. controls | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||||||
| HLA-G 14 bp ins/del | del/del | 29 | 36.7 | 61 | 30.8 | 75 | 34.2 | 1 |
| ||
| del/ins | 30 | 38 | 81 | 40.9 | 91 | 41.6 | 1.02 | 0.67 | 1.53 | ||
| ins/ins | 20 | 25.3 | 56 | 28.3 | 53 | 24.2 | 1.19 | 0.75 | 1.90 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.23 | 0.18 | 0.16 | ||||||||
| HLA-G −725 | CC | 43 | 54.5 | 142 | 71.7 | 145 | 66.2 | 1 |
| ||
| CG | 31 | 39.2 | 46 | 23.3 | 55 | 25.1 | 1.10 | 0.73 | 1.65 | ||
| CT | 3 | 3.8 | 6 | 3 | 12 | 5.5 | 0.60 | 0.25 | 1.42 | ||
| GG | 2 | 2.5 | 3 | 1.5 | 5 | 2.3 | 0.78 | 0.24 | 2.61 | ||
| GT | 0 | 0 | 1 | 0.5 | 2 | 0.9 | 0.47 | – | – | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| –0.09 | –0.008 | 0.008 | ||||||||
| HLA-G −716 | TT | 28 | 35.4 | 42 | 21.2 | 52 | 23.7 | 1 |
| ||
| GT | 27 | 34.2 | 95 | 48 | 105 | 47.9 | 0.86 | 0.56 | 1.35 | ||
| GG | 24 | 30.4 | 61 | 30.8 | 62 | 28.3 | 1.02 | 0.63 | 1.65 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.314 | 0.031 | 0.039 | ||||||||
| KIR2DL4 9620 | 9A/9A | 22 | 27.8 | 59 | 29.8 | 74 | 33.8 | 1 |
| ||
| 9A/10A | 42 | 53.2 | 103 | 52 | 95 | 43.4 | 1.39 | 0.93 | 2.09 | ||
| 10A/10A | 15 | 19 | 36 | 18.2 | 50 | 22.8 | 0.93 | 0.57 | 1.54 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| –0.072 | –0.055 | 0.122 | ||||||||
| KIR2DL4 9571 | TT | 22 | 27.8 | 59 | 29.8 | 78 | 35.6 | 1 |
| ||
| CT | 42 | 53.2 | 103 | 52 | 95 | 43.4 | 1.47 | 0.98 | 2.20 | ||
| CC | 15 | 19 | 36 | 18.2 | 46 | 21 | 1.07 | 0.64 | 1.76 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| –0.072 | –0.055 | 0.113 | ||||||||
| KIR2DL4 9769 | CC | 53 | 67.1 | 144 | 72.7 | 170 | 77.6 | 1 |
| ||
| CA | 23 | 29.1 | 45 | 22.7 | 42 | 19.2 | 1.39 | 0.90 | 2.15 | ||
| AA | 3 | 3.8 | 9 | 4.6 | 7 | 3.2 | 1.44 | 0.57 | 3.64 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.028 | 0.15 | 0.14 | ||||||||
| KIR2DL4 9797 | GG | 22 | 27.8 | 56 | 28.3 | 77 | 35.2 | 1 |
| ||
| GA | 42 | 53.2 | 107 | 54 | 97 | 44.3 | 1.51 | 1.01 | 2.27 | ||
| AA | 15 | 19 | 35 | 17.7 | 45 | 20.5 | 1.10 | 0.66 | 1.82 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| –0.072 | –0.093 | 0.095 | ||||||||
| LILRB1 5651 | GG | 66 | 83.5 | 162 | 81.8 | 190 | 86.7 | 1 |
| ||
| GA | 10 | 12.7 | 28 | 14.1 | 24 | 11 | 1.31 | 0.76 | 2.25 | ||
| AA | 3 | 3.8 | 8 | 4.1 | 5 | 2.3 | 1.74 | 0.62 | 4.90 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W |
|
|
| ||||||||
|
| 0.3 | 0.28 | 0.235 | ||||||||
Cases A patients with two miscarriages; Cases B patients with three or more miscarriages, N number of cases, P probability, OR odds ratio, 95 % CI confidence interval, H-W Hardy–Weinberg equilibrium, f < 0 correspond to deficiency of homozygotes, f > 0 correspond to excess of homozygotes, f = 0 in case of H-W
a Frequencies of KIR2DL4 polymorphisms in Controls were described previously by Nowak et al. (2015). b Odds ratio computed for [cases A plus cases B] vs. controls
Estimated odds ratios (OR) in model for odds of miscarriage by HLA-G (–716), LILRB1 (rs41308748) and KIR2DL4 polyA polymorphisms
| Polymorphism | OR | CI 95 % |
| |
|---|---|---|---|---|
| HLA-G −716 women: GT | 0.64 | 0.43 | 0.93 | 0.0206 |
| LILRB1 women: GA | 0.40 | 0.19 | 0.82 | 0.0131 |
| KIR2DL4 men: 9A/10A | 1.49 | 1.04 | 2.13 | 0.0288 |
| HLA-G −716 women: GT × LILRB1 women: GA | 0.62 | 0.22 | 1.76 | 0.0761 |
detR 3×3 = 0.998; quasi-R2 = 0.0266
χ df=42 = 13.35, p = 0.00968
β 0 = 0.3955 CI 95 % (0.074; 0.717)
Woman: HLA-G (–716) not GT & LILRB1 not GA plus partner KIR2DL4 not 9A/10A assumed as baseline
P probability, OR odds ratio, CI 95 % confidence interval
Haplotype frequencies of HLA-G polymorphisms in men and women group among miscarriages cases and controls, sorted by frequency in cases women
| HLA-G haplotypes | Women | Men | ||||||
|---|---|---|---|---|---|---|---|---|
| ins/del | −725 | −716 | Cases (%) | Controls (%) | RR | Cases (%) | Controls (%) | RR |
| ins | C | G | 37.85 | 39.00 | 0.97 | 46.7 | 41.78 | 1.12 |
| del | C | T | 33.59 | 37.66 | 0.89 | 30.05 | 29.22 | 1.03 |
| del | G | T | 15.63 | 14.55 | 1.07 | 13.11 | 15.30 | 0.86 |
| del | C | G | 10.64 | 6.66 | 1.60 | 8.10 | 10.50 | 0.77 |
| ins | T | T | 2.02 | 1.10 | 1.84 | 1.77 | 3.20 | 0.55 |
| ins | G | T | 0.28 | 0.74 | 0.38 | 0.27 | 0.00 | – |
| Σ | 100 | 99.71 | – | 100 | 100 | – | ||
| Cases vs. controls |
|
| ||||||
Ins 14 bp insertion in 3′UTR of HLA-G, Del 14 bp deletion in 3′UTR of HLA-G, RR ratio Cases/Controls, P probability, H Hellinger distance